Innovative commercial engagement model for life sciences companies
improves customer alignment
DANBURY, Conn. & SAN FRANCISCO--(BUSINESS WIRE)--
IQVIA™
(NYSE:IQV) today announced that Napo Pharmaceuticals, Inc. (Napo), a
wholly-owned subsidiary of Jaguar Health, Inc., has selected Orchestrated
Customer Engagement (OCE), IQVIA Technologies’ innovative commercial
solutions suite, to support Napo’s growing commercial organization and
enable it to work more closely with healthcare providers.
Napo will use the OCE technology platform for its product, Mytesi®,
an FDA-approved antidiarrheal indicated for the symptomatic relief of
noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral
therapy (ART).
“Mytesi has a robust pipeline of potential follow-on indications, and
using IQVIA’s integrated solution, OCE, will help our commercial teams
better serve and work more closely with healthcare providers,” said
Robert Griffing, chief commercial officer of Napo. “With improved
efficiencies and advancements for our field sales and home office teams,
we can push our growing commercial organization to the next level.”
IQVIA Technologies’ OCE transforms life sciences companies’ commercial
operations from independent silos to insight-fueled, orchestrated
departments focused on highly relevant and contextual customer
engagement actions. By applying artificial intelligence and intuitive
user interfaces, the intraoperative OCE platform increases efficiency
across all functions, channels, and stakeholders. This leads to reduced
friction, enhanced productivity, increased value, and better decision
making among customers.
“With IQVIA’s OCE, Napo saw the opportunity to have a best-in-class
technology suite, and we are thrilled they took advantage of it,” said
Tal Rosenberg, senior vice president, Global Technology Solutions at
IQVIA. “OCE will help Napo increase the value of its customer
interactions by offering a more intelligent and coordinated customer
experience that ultimately will yield better health outcomes.”
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
the information that helps its customers drive human health outcomes
forward. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers, and other healthcare stakeholders tap into
a deeper understanding of diseases, human behaviors, and scientific
advances, in an effort to advance their path toward cures. To learn
more, visit www.iqvia.com.
About Mytesi
®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic
relief of noninfectious diarrhea in adult patients with HIV/AIDS on
antiretroviral therapy (ART). Mytesi is not indicated for the treatment
of infectious diarrhea. Rule out infectious etiologies of diarrhea
before starting Mytesi. If infectious etiologies are not considered,
there is a risk that patients with infectious etiologies will not
receive the appropriate therapy and their disease may worsen. In
clinical studies, the most common adverse reactions occurring at a rate
greater than placebo were upper respiratory tract infection (5.7%),
bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased
bilirubin (3.1%).
See full Prescribing Information at Mytesi.com.
Crofelemer, the active ingredient in Mytesi, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the Amazon rainforest.
Napo has established a sustainable harvesting program for crofelemer to
ensure a high degree of quality and ecological integrity.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company
focused on developing novel, sustainably derived gastrointestinal
products on a global basis. Our wholly-owned subsidiary, Napo
Pharmaceuticals, Inc., focuses on developing and commercializing
proprietary human gastrointestinal pharmaceuticals for the global
marketplace from plants used traditionally in rainforest areas. Our
Mytesi® (crofelemer) product is approved by the U.S. FDA for
the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS
on antiretroviral therapy.
For more information about Jaguar, please visit jaguar.health.
For more information about Napo, visit napopharma.com.
IQVIAFIN
Click
here to subscribe to Mobile Alerts for IQVIA.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181129005374/en/
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732
Andrew
Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144
Source: IQVIA